Blake Borgeson - 18 Nov 2021 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
18 Nov 2021
Net transactions value
-$182,005
Form type
4
Filing time
22 Nov 2021, 19:20:26 UTC
Previous filing
05 Oct 2021
Next filing
09 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $34,811 -1,900 -0.02% $18.32 7,687,191 18 Nov 2021 Direct F1, F2
transaction RXRX Class A Common Stock Sale $147,194 -7,725 -0.1% $19.05 7,679,466 18 Nov 2021 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $17.86 to $18.835 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.87 to $19.44 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.